Genascence's GNSC-001 Shows Promise in Phase 1b Trial for Knee Osteoarthritis
Key Insights
Genascence (search)'s GNSC-001 gene therapy demonstrated acceptable safety and tolerability across all doses in a Phase 1b trial for knee osteoarthritis (search).
The DONATELLO trial showed GNSC-001 achieved and maintained target levels of IL-1Ra expression in synovial fluid over six months.
Short steroid courses supported higher levels of transgene expression, informing the design of a Phase 2 clinical trial.
Genascence (search) Corporation announced positive six-month interim safety and biomarker results from its Phase 1b DONATELLO clinical trial evaluating GNSC-001, an investigational AAV gene therapy for knee osteoarthritis (search) (OA). The data indicate that GNSC-001, which encodes interleukin 1 receptor antagonist (search) (IL-1Ra), was safe and well-tolerated across multiple dosing arms.
The six-month analysis demonstrated that GNSC-001 achieved acceptable safety and tolerability across all doses tested, along with encouraging biomarker data. Mean IL-1Ra expression reached and maintained target levels in synovial fluid throughout the six-month follow-up period. The study also found that immune-conditioning with a short steroid course supported higher levels of transgene expression.
Clinical Significance
"These six-month interim results mark a critical milestone in our mission to transform the treatment paradigm for osteoarthritis (search)," said Jeymi Tambiah, M.D., chief medical officer of Genascence (search). "The safety profile and sustained IL-1Ra expression data underscore the promise of GNSC-001 as a potential one-time gene therapy for this debilitating condition. The results from DONATELLO will guide discussions with regulatory authorities as Genascence prepares to initiate a Phase 2 trial focused on clinical efficacy."
Targeting IL-1 in Osteoarthritis
Annahita Keravala, Ph.D., chief scientific officer of Genascence (search), highlighted the significance of these findings: "The ability to locally and sustainably inhibit IL-1 (search) activity in the joint has been a long-standing goal in osteoarthritis (search) research. GNSC-001 is the first IL-1 inhibitor that has been shown to generate IL-1Ra expression levels that reach and maintain therapeutic thresholds in the synovial fluid long-term following a single administration. This highlights the potential of our gene therapy approach to address a key mediator of inflammation and disease progression in osteoarthritis and offers hope for a transformative treatment option for patients."